Drugs moving into the clinic: 17
The seventeenth in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| Serenex | SNX-5422 | Oncology | Heat shock protein 90 (Hsp90) inhibitor |
| Valeant Pharma- ceuticals International | Retigabine | CNS - pain associated with post-herpetic neuralgia (PHN) | First-in-class neuronal potassium channel opener currently in Phase III development as an adjunctive treatment for partial-onset seizures in patients with refractory epilepsy |
| Zippharm Oncology | ZIO-101 (darinaparsin) | Oncology | oral capsule form of small molecule organic arsenic N.B. Injectable form in Phase II |
| Suven Life Sciences | Arylcarbonyl- indole | CNS - Alzheimer's | Tetracyclic Arylcarbonyl- indoles bind to Serotonin (5-HT) Receptor N.B. IND application |
| GW Pharma- ceuticals | Delta-9-tetrahydro- cannabivarin (THCV) | Metabolism - obesity, diabetes | Cannabinoid product to inhibit CB1 and CB2 receptors |
